Detalhe da pesquisa
1.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
Blood
; 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437498
2.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441846
3.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood
; 141(11): 1265-1276, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265087
4.
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Lancet Oncol
; 25(3): 388-399, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423051
5.
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
Br J Haematol
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603594
6.
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
Br J Haematol
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724457
7.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
8.
The role of therapy in the outcome of patients with myelofibrosis.
Cancer
; 129(18): 2828-2835, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243913
9.
Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
Cancer
; 129(4): 531-540, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477735
10.
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
Cancer
; 129(2): 175-180, 2023 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36397669
11.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
12.
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Cancer
; 129(7): 1017-1029, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36715486
13.
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Cancer
; 129(12): 1856-1865, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892949
14.
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.
Oncologist
; 28(11): e1065-e1074, 2023 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156009
15.
Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2).
Haematologica
; 108(9): 2331-2342, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951163
16.
Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.
Am J Hematol
; 98(8): 1176-1184, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37139921
17.
Improved survival of patients with myelofibrosis in the last decade: Single-center experience.
Cancer
; 128(8): 1658-1665, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35077575
18.
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
Cancer
; 128(14): 2736-2745, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35452134
19.
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
Am J Hematol
; 97(3): 329-337, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981570
20.
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Cancer
; 127(20): 3772-3781, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34255353